Back to search results

Cleaner Vac® Thrombectomy System for Deep Vein Thrombosis (DVT)

This study is looking at the safety and effectiveness of the Cleaner Vac® Thrombectomy System. This device helps remove blood clots (thrombus) from veins, specifically in your legs (lower extremity proximal deep vein thrombosis, or DVT). You might be able to join if you are at least 18 years old and will be treated with the Cleaner Vac® Thrombectomy System for a blood clot in your peripheral veins. The study will measure how successful the procedure is right away and check for any major problems within 30 days after the procedure. The current status of this study is unclear, but it plans to enroll 185 people.

Study design
This is an observational, multi-center, open-label study that plans to enroll 185 participants.
What's involved
You would need to undergo treatment with the Cleaner Vac® Thrombectomy System and provide written informed consent.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for 30 days after your procedure to check for any major problems.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07102160

Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking

Recruiting
Not specifiedAges 18+Observational
Argon Medical Devices
~185 participants
Updated 2026-06-16 on ClinicalTrials.gov
What's tested:Aspiration thrombectomy system

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Technical Success
Measured over At the time of the index procedure
+1 more outcome measured

Conditions

Deep Vein Thrombosis (DVT)
Thrombus in the Peripheral Venous Vasculature
Venous Embolism
Thrombus in the Central and Peripheral Circulatory System, Including Saphenous Vein Grafts

Explore related trials

Deep Vein Thrombosis

NCT07102160

Where you'd take part

This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Baycare Health System

    Tampa, Floridastudy coordinator listed

    Recruiting

  • Baylor Scott & White The Heart Hospital - Plano

    Plano, Texasstudy coordinator listed

    Recruiting

  • Janna, LLC

    Fort Lauderdale, Floridastudy coordinator listed

    Recruiting

  • St. Elizabeth Healthcare - Edgewood

    Edgewood, Kentuckystudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Pete Stibbs · STUDY_DIRECTOR · Argon Medical Devices

Who to contact

Esther Ajasa, MS
[email protected]
469-423-2280
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Technical SuccessAt the time of the index procedure

    ≥75% thrombus removal in the target venous segment, assessed by change in Marder Score

  • Composite rate of Major Adverse Events (MAEs) within 30 days post-procedure30 days post-index procedure